Aspirin Effectiveness Study
- Conditions
- Coronary Artery Disease
- Registration Number
- NCT01113060
- Lead Sponsor
- Royal College of Surgeons, Ireland
- Brief Summary
Aspirin is an effective medicine for prevention of heart attacks in patients with coronary artery disease and works by preventing clots from forming. In previous studies aspirin has been found to be ineffective in between 2% and 65% of patients but none of these studies have looked specifically at coronary artery disease patients in Ireland. This study is being done to identify the percentage of patients in Ireland whose aspirin is not working effectively and help identify factors that could be used to target interventions to increase aspirin's effectiveness in Irish patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 500
- Age 18 years or older
- Patients with documented coronary artery disease
- Current treatment with any dose of aspirin daily for a minimum of 3 months
- Able to provide written informed consent based on competent mental status
- Myocardial infarction, unstable angina or stroke during the preceding three months
- Platelet count <125,000/mm
- Known haematological disorders
- Active malignancy on current chemotherapy or a recent diagnosis of cancer
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with non-response to aspirin Following a minimum of 3 months of daily aspirin use Prevalence of non-response to aspirin in coronary artery disease patients in Ireland by measurement of serum thromboxane B2
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Beaumont Hospital
馃嚠馃嚜Dublin 9, Dublin, Ireland